Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $103,223 | $186,205 | $219,250 | $258,682 |
| - Cash | $35,627 | $66,886 | $130,101 | $122,162 |
| + Debt | $29,702 | $31,047 | $105 | $0 |
| Enterprise Value | $97,298 | $150,366 | $89,254 | $136,520 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$12,305 |
| % Margin | – | – | – | – |
| EBITDA | -$98,083 | -$51,606 | -$42,687 | -$19,580 |
| % Margin | – | – | – | – |
| Net Income | -$102,329 | -$52,371 | -$42,856 | -$100,606 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.71 | -1.08 | -1.06 | -2.63 |
| % Growth | -58.3% | -1.9% | 59.7% | – |
| Operating Cash Flow | -$86,215 | -$43,064 | -$35,153 | -$17,961 |
| Capital Expenditures | -$16 | -$21 | -$161 | -$40 |
| Free Cash Flow | -$86,231 | -$43,085 | -$35,314 | -$18,001 |